AADI vs. BNTC, SNDL, RZLT, AVIR, LFCR, ITOS, ACIU, AMLX, CADL, and PROC
Should you be buying Aadi Bioscience stock or one of its competitors? The main competitors of Aadi Bioscience include Benitec Biopharma (BNTC), SNDL (SNDL), Rezolute (RZLT), Atea Pharmaceuticals (AVIR), Lifecore Biomedical (LFCR), iTeos Therapeutics (ITOS), AC Immune (ACIU), Amylyx Pharmaceuticals (AMLX), Candel Therapeutics (CADL), and Procaps Group (PROC). These companies are all part of the "pharmaceutical products" industry.
Aadi Bioscience vs.
Benitec Biopharma (NASDAQ:BNTC) and Aadi Bioscience (NASDAQ:AADI) are both small-cap medical companies, but which is the better stock? We will compare the two businesses based on the strength of their profitability, earnings, media sentiment, analyst recommendations, dividends, risk, institutional ownership, valuation and community ranking.
Benitec Biopharma received 183 more outperform votes than Aadi Bioscience when rated by MarketBeat users. Likewise, 65.32% of users gave Benitec Biopharma an outperform vote while only 39.29% of users gave Aadi Bioscience an outperform vote.
Benitec Biopharma has a beta of 0.82, indicating that its stock price is 18% less volatile than the S&P 500. Comparatively, Aadi Bioscience has a beta of 0.73, indicating that its stock price is 27% less volatile than the S&P 500.
Benitec Biopharma presently has a consensus target price of $24.43, indicating a potential upside of 101.89%. Aadi Bioscience has a consensus target price of $1.67, indicating a potential downside of 48.88%. Given Benitec Biopharma's stronger consensus rating and higher probable upside, research analysts plainly believe Benitec Biopharma is more favorable than Aadi Bioscience.
In the previous week, Benitec Biopharma had 2 more articles in the media than Aadi Bioscience. MarketBeat recorded 7 mentions for Benitec Biopharma and 5 mentions for Aadi Bioscience. Aadi Bioscience's average media sentiment score of 1.89 beat Benitec Biopharma's score of 1.56 indicating that Aadi Bioscience is being referred to more favorably in the news media.
Benitec Biopharma has higher earnings, but lower revenue than Aadi Bioscience. Benitec Biopharma is trading at a lower price-to-earnings ratio than Aadi Bioscience, indicating that it is currently the more affordable of the two stocks.
52.2% of Benitec Biopharma shares are owned by institutional investors. Comparatively, 52.1% of Aadi Bioscience shares are owned by institutional investors. 1.3% of Benitec Biopharma shares are owned by company insiders. Comparatively, 37.3% of Aadi Bioscience shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.
Benitec Biopharma has a net margin of 0.00% compared to Aadi Bioscience's net margin of -246.06%. Benitec Biopharma's return on equity of -60.28% beat Aadi Bioscience's return on equity.
Summary
Benitec Biopharma beats Aadi Bioscience on 14 of the 19 factors compared between the two stocks.
Get Aadi Bioscience News Delivered to You Automatically
Sign up to receive the latest news and ratings for AADI and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Aadi Bioscience Competitors List
Related Companies and Tools
This page (NASDAQ:AADI) was last updated on 1/5/2025 by MarketBeat.com Staff
Free AADI Stock Alerts